Ipilimumab/nivolumabHypophysitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1965卷 / 1期

关键词：

D O I：

10.1007/s40278-023-43226-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：258 / 258

相关论文

共 50 条

[31] Ipilimumab/nivolumabHypophysitis with panhypopituitarism, central diabetes insipidus and type 1 diabetes mellitus: case report
[J]. Reactions Weekly, 2019, 1734 (1) : 293 - 293
[32] Ipilimumab/nivolumabHypophysitis and immune mediated hepatitis: 3 case reports
[J]. Reactions Weekly, 2022, 1927 (1) : 305 - 305
[33] Ipilimumab/nivolumabHypophysitis with panhypopituitarism, central diabetes insipidus and type 1 diabetes mellitus: case report
[J]. Reactions Weekly, 2018, 1713 (1) : 202 - 202
[34] Ipilimumab/nivolumabHypophysitis with adrenal crisis and thyroiditis
[J]. Reactions Weekly, 2024, 2008 (1) : 183 - 183
[35] NivolumabHypophysitis and related complications: case report
[J]. Reactions Weekly, 2019, 1757 (1) : 234 - 234
[36] Ipilimumab/nivolumabHypophysitis and ACTH-dependent hypercortisolism
[J]. Reactions Weekly, 2023, 1985 (1) : 273 - 273
[37] NivolumabHypophysitis, skin rash and pigmentation: case report
[J]. Reactions Weekly, 2019, 1742 (1) : 175 - 175
[38] NivolumabHypophysitis, hypothyroidism and central adrenal insufficiency: case report
[J]. Reactions Weekly, 2019, 1770 (1) : 306 - 306
[39] NivolumabHypophysitis leading to secondary adrenal insufficiency: case report
[J]. Reactions Weekly, 2021, 1877 (1) : 313 - 313
[40] NivolumabHypophysitis, primary hypothyroidism and secondary adrenal insufficiency: case report
[J]. Reactions Weekly, 2018, 1714 (1) : 299 - 299

← 1 2 3 4 5 →